Plateau on GLP-1: What the Trial Weight Curves Show
In this guide
This article is for information only and is not medical advice. Talk to your prescriber or a qualified professional.
A plateau on GLP-1 treatment is expected at some point. In the semaglutide trials, average weight loss was fastest in the first months, slowed, and leveled off after about 60 weeks, then held steady for as long as treatment continued. The 2025 nutrition advisory on GLP-1 therapy describes a relative plateau at around 18 months. A flat stretch on your scale is not, on its own, a sign that something is wrong. It is a good moment to review habits and goals with your care team, and your prescriber is the one to decide whether anything about your treatment should change.
About Dosinha: a shot log, reminders, injection-site rotation, weight and water are free forever. See what is free and what Pro adds.
Key points
- Average trial curves flatten over time: faster loss in the first 6 months, a plateau after roughly a year or more.
- In the trials, the plateau phase was the phase where weight stayed down while treatment continued.
- Short stalls also happen because daily weight bounces with water, food and timing.
- Bring a few weeks of notes to your prescriber rather than changing anything on your own.
For the full picture of how fast weight changed in the trials, see our pillar on GLP-1 average weight loss per week.
What the trial curves show
| Source | Population | What the curve did |
|---|---|---|
| STEP 5, semaglutide 2.4 mg | 304 adults without diabetes, 104 weeks | Substantial early loss that plateaued after about week 60 and was maintained to week 104 (mean change 15.2% vs 2.6% on placebo) |
| STEP 1 and STEP 2, as described by the STEP 5 authors | 68-week trials in adults without diabetes (STEP 1) and with type 2 diabetes (STEP 2) | Reductions in weight, waist, blood pressure and HbA1c appeared to plateau around week 60 |
| SELECT, semaglutide 2.4 mg | 17,604 adults with heart disease and no diabetes | Weight loss continued over 65 weeks and was sustained for up to 4 years |
| 2025 joint nutrition advisory (review of studies) | Adults on GLP-1 therapy for obesity | Faster in the first 6 months, slower after, relative plateau at about 18 months |
These describe group averages. Inside each average, people plateaued at different times and at different amounts of loss. The trial averages are not a prediction for you.
The tirzepatide trials report weight at 72 weeks, after at least 52 weeks on a maintenance dose, according to the Zepbound label. We did not find a published statement in the sources we read about exactly when the tirzepatide curve leveled off, so we will not give a week.
A plateau is not the same as the medicine stopping
The STEP 1 extension is useful here. Treatment stopped at week 68, after the average curve had leveled off. Over the following year, people who had been on semaglutide regained about two-thirds of the weight they had lost. That suggests the flat phase was not a phase where nothing was happening. The 2025 advisory also notes that some people stop treatment once they reach a plateau or a goal, without knowing that long-term use may be needed to keep the weight off. If you are thinking about stopping because your weight has stopped moving, talk to your prescriber first. See how long people take a GLP-1 for what labels and trials say.
Short stalls versus a true plateau
Not every flat week is a plateau. Body weight moves day to day with fluid, food and the time you weigh in. A few weeks with no change in the middle of a downward trend is common in weight loss of any kind.
Some ways to see the trend more clearly:
- Weigh at the same time of day, on the same scale, in similar clothes.
- Look at a 2 to 4 week trend rather than single readings.
- Track something besides weight. The trials also measured waist circumference, and how your clothes fit counts too.
Habits to review with your care team
The labels say these medicines are used together with a reduced-calorie diet and more physical activity. In the Wegovy trials, that meant a diet of about 500 kcal a day below usual intake and counseling toward at least 150 minutes of activity a week, according to the Wegovy prescribing information. A plateau is a reasonable time to look at those basics with a clinician or dietitian:
- Protein. The 2025 advisory stresses enough protein and resistance training to help preserve muscle while losing weight. Our guide to protein on a GLP-1 explains the ranges it gives.
- Strength work. The advisory cites modeling that, without structured strength training, muscle can make up about 10% to 15% of weight lost in women and 20% to 25% in men. More in GLP-1 muscle loss.
- Eating patterns. Smaller appetites can drift back over time. A few days of honest food notes give your dietitian something concrete.
- Side effects. Nausea or constipation can push people toward easy, low-fiber foods. Log them so your team can see the pattern.
- Sleep, stress and other medicines. Mention any new prescription to your prescriber and pharmacist.
None of this is a plan for you. Your prescriber and pharmacist set your treatment plan, and a dietitian can tailor food advice.
When to call a clinician
Talk to your prescriber if your weight stopped changing much earlier than you were told to expect, if you are gaining steadily, or if you are losing weight you did not intend after a plateau.
When to call: severe stomach pain that will not go away, with or without vomiting, sometimes spreading to the back. Upper stomach pain with fever, yellow skin or eyes, or clay-colored stools. Nausea, vomiting or diarrhea that does not go away, which can lead to dehydration and kidney problems. Swelling of the face, lips, tongue or throat, or trouble breathing or swallowing: get medical help right away.
These come from the Wegovy Medication Guide and the Zepbound label. The list is not complete.
A week of notes on side effects, food and energy can make your next visit more useful. The diary below is private to your browser and printable.
Frequently asked questions
Is it normal to plateau on a GLP-1?
Yes, in the sense that average trial curves flatten. In the semaglutide trials, loss leveled off after about 60 weeks and then held steady while treatment continued. When and where you plateau can be different.
When does the GLP-1 plateau happen?
In STEP 5, after about week 60 on semaglutide 2.4 mg. The 2025 nutrition advisory describes a relative plateau at around 18 months across studies. Earlier stalls of a few weeks are also common and often reflect normal day-to-day weight changes.
Does a plateau mean the medicine stopped working?
Not necessarily. In the STEP 1 extension, people who stopped semaglutide after the curve had leveled off regained about two-thirds of their loss within a year. Your prescriber can review what your plateau means for you.
How do you break a plateau on a GLP-1?
There is no proven trick. Reviewing protein, strength training, activity and eating patterns with your care team is a sensible start. Any change to your medicine is a decision for your prescriber.
Keep your own record
A plateau is easier to read with a few weeks of data. Dosinha’s free weight log, shot log, water tracking and side-effect check-ins help you keep that record and notice patterns to share with your prescriber or dietitian. The app does not break plateaus and does not change your plan. Look around Dosinha. Related: GLP-1 weight loss without diabetes.
Sources
- Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 2022.
- Ryan DH, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature Medicine, 2024.
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022.
- Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory. Obesity, 2025.
- DailyMed. Wegovy prescribing information and Zepbound prescribing information. Labels posted 2026.
This article is for information only and is not medical advice. Talk to your prescriber or a qualified professional.